Please login to the form below
5
Revenue 2017Avastin
The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Avastin was produced by Roche.
Roche reports strong diagnostics sales in Q1 as demand for COVID-19 tests continues
The specific impact of biosimilars on Roche’s MabThera/Rituxan, Avastin and Herceptin franchises remained ‘significant’, particularly in the US.
Roche’s diagnostic business sales offer a bright spot in Q4
treatments Herceptin (trastuzumab), Avastin (bevacizumab) and Rituxan (rituximab).
Roche cites COVID-19 and biosimilars in Q2 decline
Much of that decline can be attributed to increasing biosimilar competition to three of Roche’s key cancer therapies – Herceptin (trastuzumab), Avastin (bevacizumab) and Rituxan (rituximab).
Tecentriq misses the mark in advanced ovarian cancer
PD-L1 inhibitor failed to improved progression-free survival. Roche’s Genentech division has reported that Tecentriq, plus Avastin, was unable to improve progression-free survival as a front-line treatment ... The phase 3 IMagyn050 study evaluated the
AZ’s comeback drug cediranib stumbles in phase 3 trial
Cediranib has been developed as a potential oral alternative to drugs like Roche’s big-selling injectable VEGF inhibitor Avastin (bevacizumab), which is already used to treat ovarian cancer and other
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
-
Publications Director
-
Competitive Salary
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
-
Associate Account Director
-
Competitive Salary
- Senior & Principal Medical Writer
-
Competitive Salary Offered
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
-
Medical Editor
-
Competitive Salary
-
Account Manager
-
Competitive Salary
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
-
Senior Medical Writer
-
Competitive Salary
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
-
Senior Account Executive
-
Competitive Salary
-
Account Management
-
Competitive Salary Offered
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Novavax is close to finalising a COVID-19 vaccine supply deal with the EU
- Merck & Co reveals plans for women’s health spinoff Organon
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- bluebird bio aiming to separate business units by year-end
- AbbVie’s Rinvoq has ‘marginal clinical benefit’ over Humira at increased cost, says ICER
- AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- China’s Sinopharm given WHO emergency use listing for COVID-19 vaccine
- Pfizer, BioNTech file for full US approval of COVID-19 vaccine
- The impact of cancer on mental health during COVID-19
- How nature can help you manage the pressures of agency life
- Moderna agrees to supply Gavi with 500 million doses for COVAX
- The new reality of building a corporate brand in pharma
- Why female mentorship is so powerful in pharma
- Novavax is close to finalising a COVID-19 vaccine supply deal with the EU
- Lilly’s RET inhibitor Retevmo shows early promise in new cancer types
- Amgen adds Otezla to the COVID-19 candidate list
PMHub
Valid Insight
Valid Insight is an award-winning pharmaceutical global market access consultancy....
Latest intelligence
- How nature can help you manage the pressures of agency life
- Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
- How can we strike the right balance between familiarity and innovation when it comes to data presentation?
- Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
- Deep 6 AI: the smart software breathing new life into clinical trials
- Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
